Sellas Life Sciences SLS 深 沪
等待开盘 04-02 09:30:00 美东时间
4.21
-0.020
-0.47%
华盛通- 最 高4.36
- 今 开4.33
- 成交量 472.10万股
- 最 低 4.12
- 昨 收 4.23
- 总市值 7.56亿
- 52周最高 6.14
- 市盈率 静 --
- 换手率 2.63%
- 52周最低 1.11
- 委 比 -55.79%
- 总股本 1.80亿
- 历史最高 554.50
- 量 比 0.61
- 振 幅 5.67%
- 历史最低 0.4986
- 每 手 1
- 风险率 1.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
03-26 01:35
Sellas Life Sciences Group Files Shelf Prospectus For Offering Of Securities; No Terms Disclosed
-SEC Filing
03-21 05:14
SELLAS Life Sciences Gr Q4 EPS $(0.05) Beats $(0.07) Estimate
SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 37.5 percent increase over losses of $(0.08) per share
03-20 04:17
Sellas Life Sciences enrolls first patient in 80-patient Phase 2 SLS009 first-line AML trial
Sellas Life Sciences enrolls first patient in 80-patient Phase 2 SLS009 first-line AML trial Sellas reported enrollment of the first patient in a randomized Phase 2 trial of SLS009 (tambiciclib), a selective CDK9 inhibitor, in newly diagnosed first-line acute myeloid leukemia (AML). The study (NCT04
03-12 20:36
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
SELLAS Life Sciences Group announced the initiation of a Phase 2 trial for SLS009 (tambiciclib), a CDK9 inhibitor, in newly diagnosed acute myeloid leukemia (AML) patients. The trial, designed to enroll up to 80 patients, focuses on two cohorts: those unlikely to benefit from standard aza/ven therapy based on molecular profiling and those showing early resistance to aza/ven. The trial aims to utilize predictive biomarker and AI-assisted precision...
03-12 12:35
What's Going With SELLAS Life Sciences Stock On Wednesday?
SELLAS Life Sciences stock jumps over 200% in six months as cancer trial updates boost momentum and short interest tops 27%.
03-05 01:59
Sellas Life Sciences Group stellt neue Therapien für AML mit Fokus auf Galinpepimut-S und SLS009 vor
Sellas Life Sciences Group stellt neue Therapien für AML mit Fokus auf Galinpepimut-S und SLS009 vor Sellas Life Sciences Group Inc. hat eine neue Präsentation zu aktuellen Entwicklungen im Bereich der Krebstherapie veröffentlicht. Im Fokus stehen die beiden klinischen Wirkstoffkandidaten Galinpepim
02-04 05:19
Invesco BulletShares 2027 Corporate Bond ETF declares monthly distribution of $0.0695
Invesco BulletShares 2027 Corporate Bond ETF (BSCR) - $0.0695. Payable Jan 23; for shareholders of record Jan 20; ex-div Jan 16. More on Emerging Markets: The Next Phase In Market-Broadening Why I'm S...
01-19 21:27
SELLAS Life Sciences Enters Into Agreement With IMPACT-AML To Launch European Clinical Study Of SLS009
Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment U.S. enrollment evaluating SLS009 in combination with AZA/VEN in newlySupports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment U.S.
01-14 21:35
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
SELLAS Life Sciences Group与IMPACT-AML合作，利用其平台在欧洲进行SLS009临床试验，评估其与AZA/VEN在高危AML患者中的联合治疗效果。美国和欧洲的患者招募计划在2026年第一季度和第二季度开始，旨在扩展临床项目并提高资本效率。
01-14 13:30
